Dihydroartemisinin-piperaquine is the current frontline artemisinin combination therapy (ACT) for Plasmodium falciparum malaria in Cambodia but is now failing in several western provinces.
artemisinin combination therapy (ACT)
The pfcrt-CVIET chloroquine resistance haplotype dominated in the collection of P. falciparum samples from Muheza.
Sustaining the ACT adherence rates at the 2010 levels, through 2.5 years of insecurity in the study area is an achievement and suggests that if security can be improved barriers to improving health service quality and patient adherence to AL would be removed.
When controlling for patient characteristics, there was some evidence that the adjusted odds of adherence for ADDO patients was lower than that for public health facility patients.
Pharmaceutical monotherapies against human malaria have proven effective, although ephemeral, owing to the inevitable evolution of resistant parasites.
Artemisinin from the plant Artemisia annua (A. annua) L., and used as artemisinin combination therapy (ACT), is the current best therapeutic for treating malaria, a disease that hits children and adults especially in developing countries.
ACT is at least equivalent to chloroquine in effectively treating non-falciparum malaria.
Artemisinin combination therapy (ACT) has revolutionised malaria treatment.
Artemisinin combination therapy (ACT) has revolutionised malaria treatment. ACTs combine an artemisinin derivative (a relatively new group of very effective drugs with another longer-lasting drug from another class to try to reduce the risk of further resistance developing. ACTs cure over 90% of people; they also act against malaria gametocytes, so potentially reduce transmission.
This study seems to be the largest in terms of number of imported uncomplicated malaria cases treated by AP.